跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

安全信息

890898C

Avanti

DOTMA

Avanti Research™ - A Croda Brand

别名:

1,2-di-O-octadecenyl-3-trimethylammonium propane (chloride salt)

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C42H84ClNO2
CAS号:
104872-42-6
分子量:
670.57
MDL编号:
MFCD00145456
UNSPSC代码:
12352211
NACRES:
NA.25

表单

liquid

包装

pkg of 1 × 2.5 mL (890898C-25mg)
pkg of 2 × 4 mL (890898C-200mg)

制造商/商品名称

Avanti Research™ - A Croda Brand

浓度

10 mg/mL (890898C-25mg)
25 mg/mL (890898C-200mg)

应用

advanced drug delivery

脂质类型

transfection
cationic lipids

运输

dry ice

储存温度

−20°C

SMILES字符串

[H]C(C[N+](C)(C)C)(OCCCCCCCC/C=C\CCCCCCCC)COCCCCCCCC/C=C\CCCCCCCC.[Cl-]

InChI

1S/C42H84NO2.ClH/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-38-44-41-42(40-43(3,4)5)45-39-37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2;/h20-23,42H,6-19,24-41H2,1-5H3;1H/q+1;/p-1/b22-20-,23-21-;

InChI key

LDGWQMRUWMSZIU-LQDDAWAPSA-M

相关类别

应用

DOTMA is suitable for use in the synthesis of cationic microbubble.

生化/生理作用

DOTMA is a cationic lipid used as a non-viral vector for gene therapy. It exhibits effective in vitro and in vivo gene transfection. DOTMA induces a positive charge on the liposomes and thus promotes efficient liposome - cell membrane interaction.

包装

5 mL Clear Glass Sealed Ampule (890898C-200mg)
5 mL Clear Glass Sealed Ampule (890898C-25mg)

法律信息

Avanti Research is a trademark of Avanti Polar Lipids, LLC

通常也和此产品一起购买

产品编号
说明
价格

象形图

Skull and crossbonesHealth hazard
GHS06,GHS08

警示用语：

Danger

危险分类

Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 Oral - STOT SE 3

靶器官

Liver,Kidney, Respiratory system

储存分类代码

6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

WGK

WGK 3

闪点(°F)

does not flash

闪点(°C)

does not flash

法规信息

易制毒化学品（2类）
危险化学品

从最新的版本中选择一种：

分析证书(COA)

Lot/Batch Number

抱歉，我们目前尚未线上提供该产品的COA。

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

The use of cationic microbubbles to improve ultrasound-targeted gene delivery to the ischemic myocardium
Sun L, et al.
Biomaterials, 34(8), 2107-2116 (2013)
Yun Wu et al.
Molecular therapy. Nucleic acids, 2, e84-e84 (2013-04-18)
MicroRNA-29b (miR-29b) expression has been shown to be reduced in non-small-cell lung cancer (NSCLC) tissues. Here, we have identified the oncogene cyclin-dependent protein kinase 6 (CDK6) as a direct target of miR-29b in lung cancer. We hypothesized that in vivo
Jinhong Meng et al.
Scientific reports, 10(1), 1046-1046 (2020-01-25)
P53 mutations are responsible for drug-resistance of tumour cells which impacts on the efficacy of treatment. Alternative tumour suppressor pathways need to be explored to treat p53- deficient tumours. The E3 ubiquitin ligase, ITCH, negatively regulates the tumour suppressor protein
Jayesh A Kulkarni et al.
ACS nano, 12(5), 4787-4795 (2018-04-04)
Lipid nanoparticles (LNPs) containing short interfering RNA (LNP-siRNA) and optimized ionizable cationic lipids are now clinically validated systems for silencing disease-causing genes in hepatocytes following intravenous administration. However, the mechanism of formation and certain structural features of LNP-siRNA remain obscure.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门